Try the modernized beta website. Learn more about the modernization effort.
Working… Menu

Pravastatin and Ventilatory Associated Pneumonia (EPRAVAP)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00702130
Recruitment Status : Completed
First Posted : June 20, 2008
Last Update Posted : November 30, 2011
Information provided by (Responsible Party):
Efstratios Manoulakas, University of Thessaly

Brief Summary:

Statins present anti-inflammatory and immunomodulatory effects. They may modify the regulation of cytokines, (released from the cellular damage) and may reduce the production of C-reactive protein levels. It has been hypothesized that these pleiotropic characteristic of statins might be useful in the management of various diseases, including pneumonia. Indeed, a recent study showed that statin treatment is associated with reduced risk of pneumonia in diabetic patients. However, the relationship between statins and reduced risk of pneumonia is not consistent . In addition there is no prospective study to investigate the role of statins in severe forms of pneumonia such as the VAP.

On this base the investigators aim to study prospectively the effect of statins on the outcome of patients with VAP in the ICU settings. The investigators therefore contacted a double open label randomized trial to investigate whether the use of pravastatin reduces the incidence of Ventilator Associated Pneumonia in the ICU and whether it is related with favorable outcome of patients with Ventilator Associated Pneumonia.

Condition or disease Intervention/treatment Phase
Ventilator Associated Pneumonia Drug: Pravastatin Early Phase 1

Show Show detailed description

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 152 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Single (Investigator)
Primary Purpose: Prevention
Official Title: The Effect of Pravastatin on the Incidence and in the Natural Course of Ventilatory Associated Pneumonia in the Intensive Care Unit Patients
Study Start Date : June 2008
Actual Primary Completion Date : April 2010
Actual Study Completion Date : April 2010

Arm Intervention/treatment
Experimental: A
this arm will receive Pravastatin 40 mg per os daily
Drug: Pravastatin
pravastatin 40mg per os once daily

No Intervention: 1

Primary Outcome Measures :
  1. Length of hospitalization in the Intensive Care Unit, morbidity in the Intensive Care Unit [ Time Frame: 1 year ]

Secondary Outcome Measures :
  1. Severity of Ventilator Associated Pneumonia [ Time Frame: 1 year ]

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   14 Years and older   (Child, Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Presence in Intensive Care Unit

Exclusion Criteria:

  • Pregnancy,
  • Pneumonia, previous use of statins,
  • Contraindications to statin use (liver dysfunction, SGOT/SGPT > 100 U/L),
  • Increased CPK (over 3 times the upper limit), (for non trauma patients) on admission,
  • Increase of CPK (over 5 times the upper limit) during hospitalization,
  • Use of substances that contraindicates simultaneous use of statins (macrolides, cyclosporine, antipyrin, cholestyramine, gemfibrosil, warfarin),
  • Malabsorption syndrome (over the first 48 hours).

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT00702130

Layout table for location information
General Hospital Larissa
Larissa, Thessalia, Greece, 41221
Zakynthinos E. Dir-University Hospital Larisa
Mezourlo / Larissa, Greece, 41110
Sponsors and Collaborators
University of Thessaly
Layout table for additonal information
Responsible Party: Efstratios Manoulakas, Ph, University of Thessaly Identifier: NCT00702130    
Other Study ID Numbers: 310UT
First Posted: June 20, 2008    Key Record Dates
Last Update Posted: November 30, 2011
Last Verified: November 2011
Keywords provided by Efstratios Manoulakas, University of Thessaly:
Ventilator Associated Pneumonia
Additional relevant MeSH terms:
Layout table for MeSH terms
Pneumonia, Ventilator-Associated
Respiratory Tract Infections
Lung Diseases
Respiratory Tract Diseases
Healthcare-Associated Pneumonia
Cross Infection
Iatrogenic Disease
Disease Attributes
Pathologic Processes
Anticholesteremic Agents
Hypolipidemic Agents
Molecular Mechanisms of Pharmacological Action
Lipid Regulating Agents
Hydroxymethylglutaryl-CoA Reductase Inhibitors
Enzyme Inhibitors